vs

Side-by-side financial comparison of Polaris Inc. (PII) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.

Vertex Pharmaceuticals is the larger business by last-quarter revenue ($3.2B vs $1.7B, roughly 1.9× Polaris Inc.). Vertex Pharmaceuticals runs the higher net margin — 37.3% vs -2.8%, a 40.2% gap on every dollar of revenue. On growth, Vertex Pharmaceuticals posted the faster year-over-year revenue change (9.5% vs 8.0%). Vertex Pharmaceuticals produced more free cash flow last quarter ($348.6M vs $-342.5M). Over the past eight quarters, Vertex Pharmaceuticals's revenue compounded faster (8.9% CAGR vs -8.0%).

Polaris Inc. is an American automotive manufacturer headquartered in Medina, Minnesota, United States. Polaris was founded in Roseau, Minnesota, where it still has engineering and manufacturing facilities. The company manufactured motorcycles through its Victory Motorcycles subsidiary until January 2017, then produced motorcycles through the Indian Motorcycle subsidiary, which it purchased in April 2011 and announced its divestiture in October 2025. Polaris produced personal watercraft from 1...

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

PII vs VRTX — Head-to-Head

Bigger by revenue
VRTX
VRTX
1.9× larger
VRTX
$3.2B
$1.7B
PII
Growing faster (revenue YoY)
VRTX
VRTX
+1.5% gap
VRTX
9.5%
8.0%
PII
Higher net margin
VRTX
VRTX
40.2% more per $
VRTX
37.3%
-2.8%
PII
More free cash flow
VRTX
VRTX
$691.1M more FCF
VRTX
$348.6M
$-342.5M
PII
Faster 2-yr revenue CAGR
VRTX
VRTX
Annualised
VRTX
8.9%
-8.0%
PII

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PII
PII
VRTX
VRTX
Revenue
$1.7B
$3.2B
Net Profit
$-47.2M
$1.2B
Gross Margin
20.2%
85.4%
Operating Margin
37.8%
Net Margin
-2.8%
37.3%
Revenue YoY
8.0%
9.5%
Net Profit YoY
29.2%
30.5%
EPS (diluted)
$-0.83
$4.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PII
PII
VRTX
VRTX
Q1 26
$1.7B
Q4 25
$1.9B
$3.2B
Q3 25
$1.8B
$3.1B
Q2 25
$1.9B
$3.0B
Q1 25
$1.5B
$2.8B
Q4 24
$1.8B
$2.9B
Q3 24
$1.7B
$2.8B
Q2 24
$2.0B
$2.6B
Net Profit
PII
PII
VRTX
VRTX
Q1 26
$-47.2M
Q4 25
$-303.6M
$1.2B
Q3 25
$-15.8M
$1.1B
Q2 25
$-79.3M
$1.0B
Q1 25
$-66.8M
$646.3M
Q4 24
$10.6M
$913.0M
Q3 24
$27.7M
$1.0B
Q2 24
$68.7M
$-3.6B
Gross Margin
PII
PII
VRTX
VRTX
Q1 26
20.2%
Q4 25
20.0%
85.4%
Q3 25
20.7%
86.5%
Q2 25
19.4%
86.3%
Q1 25
16.0%
86.9%
Q4 24
20.4%
85.5%
Q3 24
20.6%
85.8%
Q2 24
21.6%
85.9%
Operating Margin
PII
PII
VRTX
VRTX
Q1 26
Q4 25
-16.7%
37.8%
Q3 25
1.1%
38.6%
Q2 25
-0.7%
38.8%
Q1 25
-2.4%
22.7%
Q4 24
3.7%
35.2%
Q3 24
3.8%
40.3%
Q2 24
6.1%
-132.9%
Net Margin
PII
PII
VRTX
VRTX
Q1 26
-2.8%
Q4 25
-15.8%
37.3%
Q3 25
-0.9%
35.2%
Q2 25
-4.3%
34.8%
Q1 25
-4.3%
23.3%
Q4 24
0.6%
31.4%
Q3 24
1.6%
37.7%
Q2 24
3.5%
-135.8%
EPS (diluted)
PII
PII
VRTX
VRTX
Q1 26
$-0.83
Q4 25
$-5.34
$4.64
Q3 25
$-0.28
$4.20
Q2 25
$-1.39
$3.99
Q1 25
$-1.17
$2.49
Q4 24
$0.18
$3.62
Q3 24
$0.49
$4.01
Q2 24
$1.21
$-13.92

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PII
PII
VRTX
VRTX
Cash + ST InvestmentsLiquidity on hand
$282.0M
$6.6B
Total DebtLower is stronger
Stockholders' EquityBook value
$750.4M
$18.7B
Total Assets
$5.2B
$25.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PII
PII
VRTX
VRTX
Q1 26
$282.0M
Q4 25
$138.0M
$6.6B
Q3 25
$335.5M
$6.3B
Q2 25
$324.3M
$6.4B
Q1 25
$291.7M
$6.2B
Q4 24
$287.8M
$6.1B
Q3 24
$291.3M
$6.5B
Q2 24
$322.7M
$5.8B
Total Debt
PII
PII
VRTX
VRTX
Q1 26
Q4 25
$1.5B
Q3 25
$1.3B
Q2 25
$1.4B
Q1 25
$1.6B
Q4 24
$1.6B
Q3 24
$1.7B
Q2 24
$2.1B
Stockholders' Equity
PII
PII
VRTX
VRTX
Q1 26
$750.4M
Q4 25
$828.4M
$18.7B
Q3 25
$1.1B
$17.3B
Q2 25
$1.2B
$17.2B
Q1 25
$1.2B
$16.5B
Q4 24
$1.3B
$16.4B
Q3 24
$1.3B
$15.6B
Q2 24
$1.3B
$14.8B
Total Assets
PII
PII
VRTX
VRTX
Q1 26
$5.2B
Q4 25
$4.9B
$25.6B
Q3 25
$5.3B
$24.9B
Q2 25
$5.4B
$24.0B
Q1 25
$5.5B
$22.9B
Q4 24
$5.5B
$22.5B
Q3 24
$5.6B
$22.2B
Q2 24
$5.7B
$20.1B
Debt / Equity
PII
PII
VRTX
VRTX
Q1 26
Q4 25
1.82×
Q3 25
1.13×
Q2 25
1.17×
Q1 25
1.32×
Q4 24
1.27×
Q3 24
1.29×
Q2 24
1.56×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PII
PII
VRTX
VRTX
Operating Cash FlowLast quarter
$498.0M
Free Cash FlowOCF − Capex
$-342.5M
$348.6M
FCF MarginFCF / Revenue
-20.6%
10.9%
Capex IntensityCapex / Revenue
4.7%
Cash ConversionOCF / Net Profit
0.42×
TTM Free Cash FlowTrailing 4 quarters
$168.0M
$3.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PII
PII
VRTX
VRTX
Q1 26
Q4 25
$178.7M
$498.0M
Q3 25
$158.8M
$1.2B
Q2 25
$320.3M
$1.1B
Q1 25
$83.2M
$818.9M
Q4 24
$206.3M
$584.6M
Q3 24
$21.0M
$1.4B
Q2 24
$146.3M
$-3.8B
Free Cash Flow
PII
PII
VRTX
VRTX
Q1 26
$-342.5M
Q4 25
$114.0M
$348.6M
Q3 25
$116.7M
$1.1B
Q2 25
$279.8M
$927.4M
Q1 25
$47.6M
$778.2M
Q4 24
$137.3M
$492.0M
Q3 24
$-32.4M
$1.3B
Q2 24
$79.1M
$-3.8B
FCF Margin
PII
PII
VRTX
VRTX
Q1 26
-20.6%
Q4 25
5.9%
10.9%
Q3 25
6.3%
37.0%
Q2 25
15.1%
31.3%
Q1 25
3.1%
28.1%
Q4 24
7.8%
16.9%
Q3 24
-1.9%
47.0%
Q2 24
4.0%
-144.5%
Capex Intensity
PII
PII
VRTX
VRTX
Q1 26
Q4 25
3.4%
4.7%
Q3 25
2.3%
3.3%
Q2 25
2.2%
4.9%
Q1 25
2.3%
1.5%
Q4 24
3.9%
3.2%
Q3 24
3.1%
2.4%
Q2 24
3.4%
2.6%
Cash Conversion
PII
PII
VRTX
VRTX
Q1 26
Q4 25
0.42×
Q3 25
1.15×
Q2 25
1.04×
Q1 25
1.27×
Q4 24
19.46×
0.64×
Q3 24
0.76×
1.31×
Q2 24
2.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PII
PII

Segment breakdown not available.

VRTX
VRTX

TRIKAFTAKAFTRIO$2.6B81%
ALYFTREK$380.1M12%
Manufactured Product Other$237.4M7%

Related Comparisons